Are We Following Guidelines for H. Pylori Treatment and Follow-up?

Amanda Walker MD, Yanet Ravelo MD, Ravi Upadhyay MD, Vincent Wong MD, Nicole Reynoso-Vasquez MD, Anjella Manoharan MD, Karishma Khetani MD, Kristen Wong MD, and Alan Tso MD

Departments of Internal Medicine and Pediatrics, Rutgers New Jersey Medical School

Background
According to American College of Gastroenterology (ACG) guidelines, testing for Helicobacter pylori (H. pylori) should be performed only if the clinician plans to offer treatment for positive results. Eradication confirmatory testing or re-testing should occur at least 4 weeks after the completion of antibiotic therapy and after proton-pump inhibitor therapy has been withheld for 1–2 weeks. Stool antigen testing has comparable accuracy to other testing modalities.

ACG Guidelines

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Since all patients with a positive test of active infection with H. pylori should be offered treatment, the critical issue is which patients should be tested for the infection.</td>
<td>Strong</td>
</tr>
<tr>
<td>All patients with active peptic ulcer disease (PUD), a past history of PUD, or a history of endoscopic resection of early gastric cancer should be tested for H. pylori infection.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm feature, non-endoscopic testing for H. pylori infection is a consideration.</td>
<td>Conditional</td>
</tr>
<tr>
<td>In patients taking long-term, low-dose aspirin, or initiating treatment with NSAID testing for H. pylori infection could be considered to reduce the risk of ulcer bleeding.</td>
<td>Conditional</td>
</tr>
<tr>
<td>Patients with unexplained iron deficiency anemia despite appropriate evaluation and adults with ITP should be tested for H. pylori.</td>
<td>Conditional</td>
</tr>
</tbody>
</table>

Aim
Our aim is to evaluate if our clinic follows the ACG guidelines for testing, retesting and treatment of patients with H. pylori. Trends and gaps in testing, treatment and retesting will be investigated. This data will be utilized to implement alterations to current practice to improve quality of care provided to these patients.

References

Methods
A retrospective chart review of patients with diagnoses of dyspepsia or gastroesophageal reflux disease (GERD) who were seen in our clinic from January 1, 2020 to December 31, 2020 was performed. We identified the frequency of screening for H. pylori, retesting and the mode of testing.

Results
A total of 124 patients were diagnosed with GERD or dyspepsia. Sixty percent (74/124) were tested for H. pylori, 73% (54/74) by endoscopy and 27% (20/74) by stool antigen. Thirty percent (22/74) tested positive for H. Pylori and 100% of those patients were treated. Eradication confirmatory testing rate was 78% (18/22). The majority of retesting was performed by stool antigen (67%; 12/18). Twenty-two percent (4/18) were re-tested by endoscopy and 11% (2/18) were re-tested by urea breath test. Seventeen percent (3/18) of patients who were retested were found to be positive.

Conclusions
In 2000, Everhart et al found 32.5% in their cohort were seropositive for H. pylori, which was consistent with our findings. Our clinic follows ACG guidelines for initial testing and treatment, but eradication confirmatory testing rate was identified as an area of improvement. Endoscopy was the preferred mode of initial testing; however, stool antigen and urea breath test may be a more cost effective alternative and a more patient-friendly way of both initial and re-testing.